Prognostic factors for IB2-IIIB cervical cancer patients treated by radiation therapy with high-dose-rate brachytherapy in a single-institution study

Yu-Ting Xiu, MM, Fan-Xu Meng, MD, Zhuo Wang, MM, Kang-Kang Zhao, MM, Yun-Long Wang, MM, Zhi-Shen Chen, MM, Bao-Sheng Sun, MD

Department of Radiotherapy, Tumor Hospital of Jilin Province, Changchun, China

Abstract

**Purpose**: To evaluate the efficacy of radiotherapy in locally advanced cervical cancer, and to determine the factors affecting prognosis.

**Material and methods**: Clinical data of 211 patients with cervical cancer, treated at our institution between June 2014 and February 2017 were reviewed retrospectively. All patients were treated with definitive radiotherapy and received external irradiation of 45-50.4 Gy. High-dose-rate brachytherapy (HDR-BT) of 24-36 Gy was prescribed to a high-risk clinical target volume (HR-CTV) as a local boost. All statistical analyses were performed with SPSS version 19.0 using Kaplan-Meier survival test and Cox regression analysis. Additionally, dose parameters of patients with IIIB stage treated with combined intracavitary/interstitial (IC/IS) implants were compared with IC only.

**Results**: With a median follow-up time of 69 months, local control (LC), overall survival (OS), disease-free survival (DFS), and nodal control (NC) at 5 years were 89%, 78%, 67%, and 88%, respectively. In multivariate analysis, the major determinant of LC was the level of pre-treatment squamous cell carcinoma antigen (SCC-Ag). The predictors of shorter OS were adenocarcinoma, pre-treatment SCC-Ag, and FIGO stage. Worse DFS was associated with adenocarcinoma, pre-treatment SCC-Ag, and involved lymph nodes. The predictors for nodal failure were positive pelvic lymph nodes. Patients with IIIB treated with IC/IS brachytherapy tended to improve DFS compared with IC alone, and obtained similar HR-CTV $D_{90}$ $EQD_2$ ($n = 10$) and biological effective dose (BED), $91 \pm 6$ Gy vs. $89 \pm 3$ Gy, and $107 \pm 4.5$ Gy vs. $107 \pm 5.6$ Gy, whereas decreased organs at risk (OARs) doses, including rectum and bladder $D_{2cm3}$ were 7.5 Gy and 7.2 Gy lower, respectively. Late grade 3-4 bladder and bowel toxicities were observed in 1.9% of patients.

**Conclusions**: Radiation therapy carried out in our institution results in good survival, with acceptable toxicity in locally advanced cervical cancer. Different individualized therapeutic strategies should be considered for patients with high-risk factors.

**Key words**: cervical cancer, prognostic factors, efficacy, radical radiotherapy.

Purpose

Despite effective screening and vaccination against human papillomavirus, the incidence of cervical cancer in China remains at a relatively high level, with more than 100,000 new cases each year, accounting for nearly 18% of the total new cases worldwide [1]. Radiotherapy can be used not only as means of radical treatment for locally advanced cervical cancer (LACC), but also as auxiliary treatment in early post-operative cervical cancer patients. Concomitant chemoradiotherapy (CCRT), consisting of platinum-based chemotherapy with external-beam radiotherapy (EBRT) followed by brachytherapy, is considered the standard treatment approach and has been widely used in clinical practice. Previous studies reported 5-year overall survival rates ranging from 61.9% to 77.9% in LACC patients [2-4]. Differences of this magnitude have major implications in a number of clinical tasks, such as stratification in trials, matched-pair analysis, decision regarding adjuvant treatment, patient counseling, and comparison of outcomes between centers and studies [5]. Many prognostic factors have been confirmed in cervical cancer patients treated with CCRT, including stage [2, 3], age [6], tumor size [7], lymph node metastasis [2, 4, 8], histological type [8], concurrent chemotherapy [9, 10], serum squamous cell carcinoma antigen (SCC-Ag) [11], overall treatment time (OTT) [12], and anemia [13]. This retrospective study aimed to report our institutional ex-
perience of curative radiotherapy in patients with LACC and evaluate prognostic factors.

**Material and methods**

**Patients**

Clinical data of 211 patients with International Federation of Gynecology and Obstetrics (FIGO) 2009 stage IB2-IIIB cervical cancer treated in our institution between June 2014 and February 2017 were reviewed retrospectively. Inclusion criteria were as follows: 1) Biopsy-diagnosed cervical SCC or adenocarcinoma (AC), 2) Locally advanced disease (FIGO IB2-IIIB), and 3) No previous surgery or external-beam radiation therapy for cervical cancer. Pre-treatment evaluations consisted of complete medical histories, physical examinations, full blood counts, biochemical profiles, serum SCC-Ag levels, pelvic magnetic resonance imaging (MRI) or computed tomography (CT), abdominal CT, and chest X-ray or thoracic CT. Positron emission tomography (PET) was optional. Enlarged lymph nodes with a short diameter ≥ 0.8 cm and/or detected as positive by functional imaging techniques, such as PET-CT or diffusion-weighted MRI, were considered to be clinical lymph node metastasis [8]. The study was approved by the Jilin Province Cancer Hospital Institution Review Board.

**Treatment**

Treatment comprised of EBRT to the pelvis with concomitant chemotherapy, followed by high-dose-rate (HDR) intra-cavitary (IC) alone or intracavitary/interstitial (IC/IS) brachytherapy based on CT. The treatment field extended from the L4-5 interspace to 3 cm below the most distal vaginal or cervical site of disease. Para-aortic radiotherapy was applied in patients considered at high risk for para-aortic nodal metastasis at the discretion of the treating physician. Clinical target volume (CTV) covered gross tumor volume (GTV), cervix, uterus, parametrium, upper part of the vagina, and drainage area of pelvic lymph nodes. CTV of para-aortic lymph nodes included any enlarged para-aortic lymph nodes plus a 0.5-1 cm margin radially, and vascular structures, such as the aorta and inferior vena cava. CTV plus an 8-10 mm margin was defined as planning target volume (PTV). GTVnd contained all positive regional lymph nodes. Planning gross tumor volume (PGTVnd) expanded GTVnd by a 5 mm margin. The prescribed dose was given as a 1.8-2 Gy fraction daily, 5 days per week, up to a total dose of 45.0-50.4 Gy in 25 to 28 fractions to PTV. For patients with positive regional lymph nodes, 56.0-61.6 Gy was delivered to PGTVnd using concomitant integrated boost technique. Synchronous sensitization chemotherapy regimen consisting of cisplatin (40 mg/m²) was administered once a week for up to 5 weeks, as allowed by patient’s health condition.

HDR-BT was delivered twice a week with an iridium-192 (192Ir) source (Elekta) after a 3rd week of EBRT, if patients were suitable. CT imaging was performed to support real-time treatment plan determination after applicator implantation. All high-risk clinical target volume (HR-CTV), intermediate-risk clinical target volume (IR-CTV), and organs at risk (OARs) were delineated according to GEC-ESTRO and ICRU recommendations [14, 15]. HR-CTV consisted of the whole cervix and residual GTV, which was composed of any manifested residual tumor extension at the time of brachytherapy and residual pathologic tissue as defined by clinical examination and MRI at that point in time, taking into account tumor extent at diagnosis. IR-CTV encompassed either tumor extension at diagnosis or a 1 cm margin around HR-CTV. The planning aim of 24-36 Gy was given to HR-CTV in 4-6 fractions. Absorbed doses to these volumes were converted into a radiobiological equivalent of 2 Gy per fraction (EQD2) and biological effective dose (BED), with an α/β value of 10 for tumors and 3 for OARs. Interstitial needles were used in patients with large tumors and parametrical involvement, especially in those with stage IIIB disease.

After stratifying for nodal status, FIGO stage, tumor load, and other important prognostic factors after completion of CCRT, some patients were administered adjuvant chemotherapy (ACT) with paclitaxel 135-175 mg/m² D1 and cisplatin 50-70 mg/m² D1-3, every 21 days in 2-4 cycles.

**Follow-up**

Our electronic case system could browse relevant information of patients’ previous examinations and treatments, from where the follow-up system exported the lists of entered patients and their telephone numbers. Then, trained professionals followed up them regularly until August 2021, and recorded events about survival and toxicities. All patients were clinically evaluated for tumor response at 3 monthly intervals for the first two years, and biannually for next three years. Radiological assessment with abdomen and chest CT and pelvic MRI was done at a 3rd month follow-up and yearly thereafter, or earlier if clinically indicated.

**Statistical analysis**

Local control (LC) was selected as the primary endpoint and defined as absence of any recurrent or progressive disease in the cervix, parametria, uterine corpus, and vagina. Overall survival, disease-free survival, nodal control, and late morbidity were secondary aims. Overall survival (OS) was defined as absence of death from any cause. Disease-free survival (DFS) was characterized as absence of any disease event or death from any cause. Nodal control (NC) was defined as absence of any recurrent or progressive nodal disease in the pelvic, inguinal, or para-aortic region. Late morbidity was described as any morbidity at 3 months or longer after end of treatment. Primary and secondary outcomes were assessed in all patients with available data. Rectal and bladder toxicity were graded according to EORTC-RTOG late toxicity criteria.

All statistical analyses were performed with SPSS version 19.0 using Kaplan-Meier survival and Cox regression analysis. T-test was applied to compare dose parameters. Time intervals for LC, OS, DFS, and NC were computed
from the date of diagnostic biopsy to the date of event or last follow-up.

Results

Patients’ characteristics

The baseline number of the patients was two hundred and fifty, and thirty-nine patients were lost to follow-up (twenty-eight) or incomplete treatment (eleven). The percentage response on tracking was 88.8%. Finally, two hundred and eleven patients were enrolled in the study, and detailed clinical characteristics are summarized in Table 1. The median age of the patients was 53.5 years, and predominance of squamous cell carcinoma (92.4%) was observed. FIGO IIB and IIIB stages were the most common stages (42.2% and 44.1%, respectively). Among the patients, 64% showed bulky tumors (> 4 cm), and 60.2% had lymph-node-negative disease. A serum SCC-Ag level ≥ 30 ng/ml at the time of diagnosis was observed in 28 (13.3%) patients. Precise radiotherapy techniques, intensity-modulated radiation therapy (IMRT), or volumetric modulated arc therapy (VMAT) were delivered in 90% of the patients. Most patients received a dose of 50 Gy or 50.4 Gy in EBRT plus 30 Gy/5 fx. brachytherapy. Only three patients were given a dose of 45 Gy during external irradiation, among them, two cases were IB2 stage and one was IIIB (refusing further external irradiation after 45 Gy/25 fx.). Five patients older than 70 years with IB2-IIIB stages received 24 Gy/4 fx. brachytherapy to reduce intestinal irradiation injury. Sixty-six patients, 90% of whom belonged to the group of IC alone, were given 36 Gy/6 fx. brachytherapy to ensure treatment effect. Their common characteristics were: IIIB, size of tumor larger than 4 cm, and poor regression after EBRT. A total of 89.1% (n = 188) of the patients received concurrent platinum-based chemotherapy, and 73.9% (n = 156) were able to tolerate 4 or more cycles. After the end of radiotherapy, 2-4 cycles of adjuvant chemotherapy were completed in eighty-six (40.8%) patients. The mean cumulative dose to 90% of HR-CTV volume (D90) was 89.24 ±5.33 Gy EQD2 (n = 10), and 82.5% (n = 174) of the patients who received ≥ 85 Gy. The mean OARs dose was 77.8 ±8.9 Gy and 81.0 ±9.9 Gy EQD2 (n = 3) to the rectum and bladder, respectively. Combined IC/IS brachytherapy was applied in 31.3% (n = 66) of the patients with persistently extensive disease, and most of them were in stage IIIB.

Outcomes and patterns of failure

With a median follow-up period of 69 months, 47 (22.3%) patients died, including 44 due to cervical cancer, 2 of heart disease, and 1 of a second primary tumor (colon cancer). A total of 59 (28%) patients experienced treatment failure, namely, 15 (7.1%) with pelvic relapse, 26 (12.3%) with distant metastasis, and 18 (8.5%) with a combination of both. The 5-year LC, OS, DFS, and NC were 89%, 78%, 67%, and 88%, respectively (Table 2, Figures 1, 2). Complete response following treatment as assessed by imaging and gynecological examination was achieved in 192 (91%) patients.

| Table 1. General characteristics of 211 patients |
| --- | --- |
| **Characteristic** | **Number, n (%)** |
| **Age (years)** |  |
| < 40 | 14 (6.6) |
| 40-60 | 132 (62.6) |
| ≥ 60 | 65 (30.8) |
| **FIGO stage** |  |
| IB2 | 11 (5.2) |
| IIA | 11 (5.2) |
| IIB | 89 (42.2) |
| IIIA | 7 (3.3) |
| IIIB | 93 (44.1) |
| **Histological type** |  |
| SCC | 195 (92.4) |
| AC | 16 (7.6) |
| **Tumor size (cm)** |  |
| < 4 | 76 (36.0) |
| ≥ 4 | 135 (64.0) |
| **Positive PLNs** |  |
| Yes | 84 (39.8) |
| No | 127 (60.2) |
| **Pre-treatment SCC-Ag (ng/ml)** |  |
| < 30 | 183 (86.7) |
| ≥ 30 | 28 (13.3) |
| **Concurrent chemotherapy (cycles)** |  |
| 1-3 | 32 (15.2) |
| ≥ 4 | 156 (73.9) |
| 0 | 23 (10.9) |
| **Adjuvant chemotherapy (2-4 cycles)** |  |
| Yes | 86 (40.8) |
| No | 125 (59.2) |
| **Radiotherapy technique** |  |
| IMRT or VMAT | 190 (90.0) |
| 3D-CRT | 21 (10.0) |
| **Brachytherapy technique** |  |
| IC/IS | 66 (31.3) |
| IC | 145 (68.7) |
| **HR-CTV (D90)** | 89.24 ±5.33 Gy (EQD2) |
| ≥ 85 Gy | 174 (82.5) |
| < 85 Gy | 37 (17.5) |
| **D2cc of rectum (EQD2)** | 77.8 ±8.9 Gy |
| **D2cc of bladder (EQD2)** | 81.0 ±9.9 Gy |
| **Overall treatment time (days)** | 53 ±8.7 |
| < 56 | 164 (77.7) |
| ≥ 56 | 47 (22.3) |

SCC—squamous cell carcinoma, AC—adenocarcinoma, PLNs—pelvic lymph nodes, IMRT—intensity-modulated radiation therapy, VMAT—volumetric modulated arc therapy, 3D-CRT—three-dimensional conformal radiation therapy, IC/IS—intracavitary/interstitial, HR-CTV—high-risk clinical target volume, D90—dose received by 90% volume, EQD2—equivalent dose in 2 Gy/fx.
Table 2. Univariate analysis of clinical outcomes

| Characteristic                  | LC % | p-value | NC % | p-value | OS % | p-value | DFS % | p-value |
|--------------------------------|------|---------|------|---------|------|---------|-------|---------|
| Overall                        | 89.0 | 0.525   | 88.0 | 0.087   | 78.0 | 0.032*  | 67.0  | 0.021*  |
| FIGO stage                     |      |         |      |         |      |         |       |         |
| IB2                            | 100.0| 0.525   | 91.0 | 0.087   | 91.0 | 0.032*  | 64.0  | 0.021*  |
| IIA                            | 91.0 | 0.525   | 82.0 | 0.087   | 82.0 | 0.032*  | 64.0  | 0.021*  |
| IIB                            | 89.0 | 0.525   | 94.0 | 0.087   | 85.0 | 0.032*  | 76.0  | 0.021*  |
| I1IA                           | 100.0| 0.525   | 86.0 | 0.087   | 86.0 | 0.032*  | 71.0  | 0.021*  |
| I1IB                           | 86.0 | 0.525   | 82.0 | 0.087   | 68.0 | 0.032*  | 59.0  | 0.021*  |
| Age (years)                    |      |         |      |         |      |         |       |         |
| < 40                           | 93.0 | 0.854   | 86.0 | 0.951   | 78.6 | 0.633   | 71.4  | 0.881   |
| 40-60                          | 89.0 | 0.854   | 87.0 | 0.951   | 79.5 | 0.633   | 68.2  | 0.881   |
| > 60                           | 88.0 | 0.854   | 89.0 | 0.951   | 73.8 | 0.633   | 67.7  | 0.881   |
| Histological type              |      |         |      |         |      |         |       |         |
| SCC                            | 88.0 | 0.685   | 87.0 | 0.179   | 80.0 | 0.001*  | 69.2  | 0.003*  |
| AC                             | 92.0 | 0.685   | 100.0| 0.179   | 41.7 | 0.001*  | 33.3  | 0.003*  |
| Positive PLNs                  |      |         |      |         |      |         |       |         |
| Yes                            | 84.0 | 0.054   | 79.0 | 0.001*  | 81.0 | 0.194   | 55.3  | 0.003*  |
| No                             | 92.0 | 0.054   | 94.0 | 0.001*  | 72.9 | 0.194   | 75.4  | 0.003*  |
| Tumor size (cm)                |      |         |      |         |      |         |       |         |
| < 4                            | 87.0 | 0.518   | 91.0 | 0.380   | 82.8 | 0.104   | 73.1  | 0.119   |
| ≥ 4                            | 89.0 | 0.518   | 86.0 | 0.380   | 73.5 | 0.104   | 63.2  | 0.119   |
| Pre-treatment SCC-Ag (ng/ml)   |      |         |      |         |      |         |       |         |
| < 30                           | 91.0 | 0.015*  | 90.0 | 0.003*  | 80.7 | 0.019*  | 71.3  | 0.003*  |
| ≥ 30                           | 76.0 | 0.015*  | 72.0 | 0.003*  | 62.1 | 0.019*  | 44.8  | 0.003*  |
| Radiotherapy technique         |      |         |      |         |      |         |       |         |
| IMRT or VMAT                   | 87.0 | 0.096   | 88.0 | 0.340   | 77.9 | 0.880   | 66.7  | 0.981   |
| 3D-CRT                         | 100.0| 0.096   | 81.0 | 0.340   | 76.2 | 0.880   | 68.4  | 0.981   |
| Cycles of concurrent chemotherapy |    | 0.554   | 0.187| 0.860   | 0.535|         |       |         |
| ≥ 4                            | 90.0 | 0.554   | 91.0 | 0.187   | 78.5 | 0.860   | 66.7  | 0.535   |
| 1-3                            | 87.0 | 0.554   | 85.0 | 0.187   | 77.1 | 0.860   | 69.5  | 0.535   |
| Adjuvant chemotherapy (2-4 cycles) | 0.406| 0.040   | 0.255| 0.340   | 0.340|         | 0.781 |         |
| Yes                            | 91.0 | 0.406   | 91.0 | 0.255   | 76.0 | 0.340   | 72.0  | 0.781   |
| No                             | 87.0 | 0.406   | 86.0 | 0.255   | 81.4 | 0.340   | 67.4  | 0.781   |
| Brachytherapy technique        |      |         |      |         |      |         |       |         |
| IC/IS                          | 88.0 | 0.647   | 88.0 | 0.925   | 78.4 | 0.800   | 67.2  | 0.750   |
| IC                             | 90.0 | 0.647   | 88.0 | 0.925   | 76.9 | 0.800   | 70.1  | 0.750   |
| HR-CTV (D90) (Gy)              |      |         |      |         |      |         |       |         |
| ≥ 85                           | 93.0 | 0.637   | 89.0 | 0.989   | 81.5 | 0.655   | 74.1  | 0.633   |
| < 85                           | 89.0 | 0.637   | 89.0 | 0.989   | 76.7 | 0.655   | 67.9  | 0.633   |
| Overall treatment time (days)  |      |         |      |         |      |         |       |         |
| < 56                           | 90.0 | 0.629   | 91.0 | 0.242   | 78.0 | 0.868   | 64.0  | 0.068   |
| ≥ 56                           | 87.0 | 0.629   | 86.0 | 0.242   | 76.6 | 0.868   | 64.0  | 0.068   |

LC – local control, NC – nodal control, OS – overall survival, DFS – disease-free survival, * p < 0.05
As demonstrated in Table 2, the univariate analysis showed that patients with pre-treatment SCC-Ag value ≥ 30 ng/ml received an inferior LC. Pathological type, pre-treatment SCC levels, and FIGO stage were significant prognostic factors for OS. In addition, DFS was also statistically impacted by positive pelvic lymph nodes (PLNs) metastasis. Similarly, PLNs and pre-treatment SCC resulted in a worse NC. Patients with bulky tumors (≥ 4 cm) tended to have poor outcomes in terms of OS and DFS, although there were no significant differences ($p = 0.104$ and $p = 0.119$).

Multivariate analysis results are shown in Table 3. The patients with AC had a worse OS (95% CI: 1.020-8.607%, $p = 0.046$) and DFS (95% CI: 1.321-6.878, $p = 0.009$) than those with SCC. Positive PLNs were associated with shorter DFS (95% CI: 1.080-3.392, $p = 0.026$) and NC (95% CI: 1.591-8.429, $p = 0.002$). The patients with pre-treatment SCC-Ag levels ≥ 30 ng/ml had a worse LC (95% CI: 1.181-6.680, $p = 0.020$), OS (95% CI: 1.132-5.405, $p = 0.023$), and DFS (95% CI: 1.033-3.828, $p = 0.040$) than those with SCC-Ag levels < 30 ng/ml. FIGO stage was an independent prognostic factor for OS (95% CI: 1.222-5.423, $p = 0.013$).

**Role of interstitial brachytherapy in IIIB stage patients**

In IIIB stage, combined IC/IS brachytherapy was used in 53% patients, and a dose ≥ 85 Gy was applied in 94.2% of these patients. IC/IS was not associated with OS or LC ($p = 0.163$ and $p = 0.262$), while DFS of patients treated with IC/IS diverged from that of the patients treated with IC ($p = 0.022$). HR-CTV D$_{90}$ (EQD$_2$, $n = 10$) in IC vs. IC/IS
was 91 ±6 Gy vs. 89 ±3 Gy, respectively (p = 0.188). There were few differences in total BED (p = 0.927) and HR-CTV \( \geq 60 \text{ cm}^3 \) (p = 0.497) between the two groups. OARs' doses (EQD\(_2\), \( n = 3 \)) were significantly affected by different methods of brachytherapy. The rectum and bladder D\(_{2cc}\) (EQD\(_2\), \( n = 3 \)) were 7.5 Gy and 7.2 Gy lower, respectively, for IC/IS vs. IC (p = 0.001 for both) (Table 4, Figure 3).

### Toxicity

Vaginal toxicity was not documented for most of the patients. Fifty-two (25.1%) patients developed chronic gastro-intestinal toxicity. Four of them (1.9%) suffered from grade 4 chronic rectal toxicity, including three patients with bowel obstruction and one with recto-vaginal fistula. The D\(_{2cc}\) rectum was 88.96 Gy, 90.44 Gy, 76.28 Gy, Table 3. Multivariate analysis of clinical outcomes (not provided in the study)

| Characteristic | LC | NC | OS | DFS |
|---------------|----|----|----|-----|
|               | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value |
| Histology     | –  | –  | 2.963 | 0.018* | 3.014 | 0.009* |
| Pre-treatment SCC-Ag | 2.850 | 0.020* | 2.153 | 0.087 | 2.473 | 0.023* | 1.988 | 0.040* |
| FIGO stages   | –  | –  | 2.574 | 0.018* | 1.668 | 0.468 |
| Positive PLNs | –  | 3.662 | 0.002* | –  | –  | 1.914 | 0.026* |

Table 4. Comparison of dosimetry and survival rate in two brachytherapy methods in IIIB stage patients

| Parameter                  | IC (n = 49) | IC/IS (n = 44) | p-value |
|----------------------------|------------|---------------|--------|
| V\(_{100}\)                | 76.0 ±32.0 | 69.0 ±22.0    | 0.283  |
| D\(_{2cc}\) of bladder (EQD\(_2\), Gy) | 86.0 ±12.0 | 79.0 ±3.0     | 0.001* |
| D\(_{2cc}\) of rectum (EQD\(_2\), Gy) | 83.0 ±12.0 | 75.0 ±4.0     | 0.001* |

**BED** – biological effective dose

**Table 3.** Multivariate analysis of clinical outcomes (not provided in the study)

**Table 4.** Comparison of dosimetry and survival rate in two brachytherapy methods in IIIB stage patients

Fig. 3. Local control (A), overall survival (B), and disease-free survival (C) according to different methods of brachytherapy

Journal of Contemporary Brachytherapy (2022/volume 14/number 4)
and 79.25 Gy EQD<sub>2</sub> (α = 3). Four (1.9%) patients developed chronic cystitis, and none of them developed grade 3 bladder toxicity (Table 5).

**Table 5.** Chronic toxicity

| Toxicity     | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|--------------|---------|---------|---------|---------|
| Rectal toxicity | 7       | 20      | 22      | 4       |
| Bladder toxicity | 1       | 3       | 0       | 0       |

**Discussion**

Cervical cancer has a high-rate of treatment failure of approximately 10-20% [16] despite treatment optimization, and pelvic relapse accounts for 70%, of which 50% is accompanied by distant metastases [16, 17]. The present study provided large-scale clinical evidence on the efficacy of CT-based three-dimensional HDR-BT in treating LACC, and emphasized the necessity for evaluating prognostic factors in refining radiation treatment strategies to improve the therapeutic ratio, which can be used as a guide for future clinical work.

In EMBRACE-I study, significant differences were found for DFS and OS using FIGO stage [18]. A retrospective analysis of several GOG trials suggested that FIGO stage was an important factor related to pelvic recurrence [19]. In our study, a significant difference in OS between FIGO stage IIIB and IIIC remained, whereas LC, NC, and DFS were not significantly different by stage, which might be related to a stronger association between image-guided brachytherapy or positive pelvic lymph nodes comparing with FIGO stage and disease progression. In the 2018 FIGO classification, imaging was introduced for a new stage IIIC1 and IIIC2 of pelvic and para-aortal nodal disease, respectively [20]. Positive PLNs can reduce OS by 35-40% [21-23]. We found that patients with positive PLNs had significantly worse DFS and NC. Intensification of nodal treatment through a simultaneously integrated boost might be better for disease control [24]. Additionally, there is a room for improvement of para-aortic nodal control, since two-thirds of nodal failures in node-positive patients occurred in the para-aortic region, with majority being outside the elective target volume [25]. Increased use of prophylactic para-aortic irradiation in high-risk node-positive patients will be investigated in our future research.

Previous studies have suggested that non-squamous histology was the strongest prognostic factor for local control [26] and metastatic spread [27]. Moreover, adenocarcinoma leads to a 10-20% lower 5-year survival rate than squamous cell cancer [28]. Our study reached a similar conclusion that patients with adenocarcinoma were more likely to die from the disease and to have disease progression, which might be due to a lower sensitivity of AC to radiotherapy and/or chemotherapy as well as an increased frequency of bulky tumors, leading to a longer time in achieving clinical remission.

Our data also suggested that patients with higher pre-treatment SCC-Ag value had inferior clinical outcomes. Kato and Torigoe first proposed that serum SCC antigen level was an effective marker that could be used to monitor the efficacy of cervical squamous cell carcinoma treatment [29]. On this basis, researchers continued to explore this biomarker and determined that SCC level was closely related to recurrence and death in patients with cervical cancer after CCRT [11, 30]. Lekskul et al. reported a clear correlation between pre-treatment SCC level and tumor size, indirectly indicating the effect of pre-treatment SCC on prognosis [31]. In addition, tumor size showed a strong association with prognosis in some studies [32-34]. In phase III RTOG 90-01 trial, large tumor size (> 5 cm) as a criterion for including patients was addressed [32]. Narayan et al. suggested that tumor volume (≥ 38 ml) was an important risk factor [33]. Beriwal et al. also reported that tumor diameter (> 5 cm) was an important predictor of increased risk of local recurrence [34]. The present study failed to confirm a clear association between tumor size and local control or disease progression, since the local tumor volume was usually within the therapeutic range of radiotherapy, whereas the effect of tumor diameter on survival would be stronger in populations mainly composed of those with stage III/IV disease, with a tumor size often beyond the therapeutic limit of radiotherapy [35].

In contrast to conventional BT, the dose was prescribed in relation to the applicator geometry rather than the anatomy of the tumor. Three-dimensional optimizations could improve tumor target dose coverage while maintaining a safe dose to OARs [36]. Previous studies demonstrated the 3-year LC of 80% for HR-CTV dose < 80 Gy; 88.8% for doses between 80 to 85 Gy and 95.6% for doses ≥ 85 Gy, and this dose-response relationship was more significant in extensive tumors [37, 38]. To reach this threshold of 85 Gy, especially in larger tumors with extensive parametrial infiltration and anatomically unfavorable topography, such as asymmetrical tumor growth, narrow vagina, or vaginal spread of disease, the use of supplemental interstitial needles combined with intra-cavitary applicators might be required [39]. Our clinical outcome showed a decline in overall local control in FIGO stage IIIB of about 6% compared with the value previously reported in EMBRACE-I study, whereas local control in IIIB stage patients receiving interstitial needles in addition to intra-cavitary treatment was close to the benchmark study [18]. The application of IC/IS did not escalate target dose of D<sub>2cm3</sub> or affect OS, receiving a significant superiority in DFS and decreased the dose of OARs when compared with IC only.

There was long-term evidence that D<sub>2cm3</sub> of the bladder and rectum was associated with urinary and gastro-intestinal side effects [40]. In our investigation, we limited majority of bladder D<sub>2cm3</sub> values to under 90 Gy, since the bladder has a higher tolerance to radiation, and the mean D<sub>2cm3</sub> to the bladder was 81.0 ±9.9 Gy. Only 4 (1.9%) patients suffered from grade 1-2 bladder late side effects, while none experienced grade 3 or above late toxicity. Our mean rectal D<sub>2cm3</sub> was 77.8 ±8.9 Gy. 9.5%, 10.4%, and 1.9% of the patients experienced grade 2, 3, and 4 rectal late side effects, respectively. The potential cause was that to meet the demand of delivered dose for HR-CTV, a fraction of patients had excessive rectal dose (more than 75 Gy), which mainly occurred in stage IIIB patients with
IC alone. The application of combined intra-cavitary/interstitial treatment showed safety and feasibility in routine practice, with clinically and statistically significant improvements in the control of disease progression and protection of OARs in LACC.

The advantage of this study was the large cohort size as well as the long follow-up time, which generated mature results. The major limitation was the lack of sufficient patients with stage I and IV disease as well as the study’s retrospective nature. Clinical data of the patients were collected from a single-center, resulting in selection bias and incomplete information. In addition, further investigations with better designs are needed to verify the findings.

Conclusions

In conclusion, EBRT with HDR-BT in patients with IB2-IIIB cervical cancer is efficacious and safe. Identifying related risk factors for prognosis to define risk groups, might be used for intensification of multi-modality treatment in high-risk patients, and reduction of treatment in low-risk patients. For patients with a poor prognosis, more individualized and systemic treatment strategies should be considered for concomitant administration with definitive radiotherapy, to improve the therapeutic ratio. These strategies include MRI-based image-guided brachytherapy, IC/IS brachytherapy with the use of interstitial needles in conjunction with tandem to optimize the radiation target volume, pelvic nodal boost, and extended field radiotherapy.

Funding

This study was supported by the Foundational Construction Fund of Jilin Province (No., 2021C043-8).

Disclosure

The authors report no conflict of interest.

References

1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249.
2. Sturdza A, Pötter R, Fokdal LU et al. Image guided brachytherapy in locally advanced cervical cancer: improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. Radioter Oncol 2016; 120: 428-433.
3. Dang YZ, Li P, Li JP et al. The efficacy and late toxicities of computed tomography-based brachytherapy with intracavitary and interstitial technique in advanced cervical cancer. J Cancer 2018; 9: 1635-1641.
4. Espernel S, García MA, Trone JC et al. From IB2 to IIIB locally advanced cervical cancers: report of a ten-year experience. Radiol Oncol 2018; 13: 16.
5. Pötter R, Tanderup K, Kirisits C et al. The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol 2018; 9: 48-60.
6. Moore KN, Java JJ, Slaughter KN et al. Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG oncology/gynecologic oncology group ancillary data analysis. Gynecol Oncol 2016; 143: 294-301.
7. Queiroz ACM, Fabri V, Mantoan H et al. Risk factors for pelvic and distant recurrence in locally advanced cervical cancer. Eur J Obstet Gynecol Reprod Biol 2019; 235: 6-12.
8. Chen CC, Wang L, Lin JC et al. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy. J Formos Med Assoc 2015; 114: 231-237.
9. Rose PG, Ali S, Watkins E et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 2804-2810.
10. Kim YS, Shin SS, Nam JH et al. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. Gynecol Oncol 2008; 108: 195-200.
11. Charakorn C, Thadanipon K, Chaijindaratana S et al. The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: A systematic review and meta-analysis. Gynecol Oncol 2018; 150: 190-200.
12. Song SS, Rudra S, Hasselle MD et al. The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. Cancer 2013; 119: 325-331.
13. Obermair A, Cheuk R, Horwood K et al. Anemia before and during concurrent chemoradiotherapy in patients with cervical carcinoma: Effect on progression-free survival. Int J Gynecol Cancer 2003; 13: 633-639.
14. Haie-Meder C, Pötter R, Limbergen EV et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radioter Oncol 2005; 74: 235-245.
15. Prescribing, recording, and reporting brachytherapy for cancer of the cervix. J ICRU 2013; 13: NP.
16. Mahantshetty U, Krishnatry R, Hande V et al. Magnetic resonance image guided adaptive brachytherapy in locally advanced cervical cancer: An experience from a tertiary cancer center in a low and middle income countries setting. Int J Radiat Oncol Biol Phys 2019; 235: 6-12.
17. Kawauchi K, Furukawa N, Kobayashi H et al. Posttreatment cut-off levels of squamous cell carcinoma antigen as a prognostic factor in patients with locally advanced cervical cancer treated with radiotherapy. J Gynecol Oncol 2013; 24: 313-320.
18. Pötter R, Tanderup K, Schmid MP et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol 2021; 22: 538-547.
19. Rose PG, Java J, Whitney CW et al. Nomograms predicting progression-free survival, overall survival, and pelvic recurrence in locally advanced cervical cancer developed from an analysis of identifiable prognostic factors in patients from NRG Oncology/Gynecologic Oncology Group randomized trials of chemoradiotherapy. J Clin Oncol 2015; 53: 2136-2142.
20. Bhatla N, Aoki D, Sharma DN et al. Cancer of the cervix uteri. Int J Gynecol Obstet 2018; 143: 23-36.
21. Parker K, Gallop-Evans E, Hanna L et al. Five years’ experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution. Int J Radiat Oncol Biol Phys 2009; 74: 140-146.
22. Atahan IL, Onal C, Ozyar E et al. Long-term outcome and prognostic factors in patients with cervical carcinoma: a retrospective study. Int J Gynecol Cancer 2007; 17: 833-842.

23. Hong JH, Tsai CS, Lai CH et al. Risk stratification of patients with advanced squamous cell carcinoma of cervix treated by radiotherapy alone. Int J Radiat Oncol Biol Phys 2005; 63: 492-499.

24. Lindegaard JC, Assenholt M, Ramlov A et al. Early clinical outcome of coverage probability based treatment planning for simultaneous integrated boost of nodes in locally advanced cervical cancer. Acta Oncol 2017; 56: 1479-1486.

25. Nommens CN, Poter R, de Leeuw AAC et al. Nodal failure after chemoradiation and MRI guided brachytherapy in cervical cancer: patterns of failure in the EMBRACE study cohort. Radiother Oncol 2019; 134: 185-190.

26. Lindegaard JC, Petric P, Lindegaard AM et al. Evaluation of a new prognostic tumor score in locally advanced cervical cancer integrating clinical examination and magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2020; 106: 754-763.

27. Xiong Y, Liu J, Chen S et al. Combination of external beam radiotherapy and californium (Cf)-252 neutron intracavity brachytherapy is more effective in control of cervical squamous cell carcinoma than that of cervical adenocarcinoma. Med Oncol 2015; 32: 231.

28. Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: a unique cervical cancer. Gynecol Oncol 2010; 116: 140-146.

29. Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977; 40: 1621-1638.

30. Oh J, Lee HJ, Lee TS et al. Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with locally advanced cervical cancer treated with radiation or chemoradiation. Obstet Gynecol Sci 2016; 59: 269-278.

31. Lekskul N, Charakorn C, Lertkhachonsuk AA et al. The level of squamous cell carcinoma antigen and lymph node metastasis in locally advanced cervical cancer. Asian Pac J Cancer Prev 2015; 16: 4719-4722.

32. Eifel PJ, Winter K, Morris M et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004; 22: 872-880.

33. Narayan K, Fisher RJ, Bernshaw D et al. Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by positron emission tomography and treated with curative intent. Int J Gynecol Cancer 2009; 19: 912-918.

34. Beriwal S, Kannan N, Sukumvanich P et al. Complete metabolic response after definitive radiation therapy for cervical cancer: patterns and factors predicting for recurrence. Gynecol Oncol 2012; 127: 305-306.

35. Endo D, Todo Y, Okamoto K et al. Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort. J Gynecol Oncol 2015; 26: 12-18.

36. Hellebust TP, Kirsits C, Berger D et al. Recommendations from gynaecological (GYN) GEC-ESTRO working group: considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy. Radiother Oncol 2010; 96: 153-160.

37. Tanderup K, Fokdal LU, Sturda A et al. Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Radiother Oncol 2016; 120: 441-446.

38. Castelnau-Marchand P, Chargari C, Maroun P et al. Clinical outcomes of definitive chemoradiation followed by intracav-